{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:15:29Z","timestamp":1794273329455,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clinthera.2023.09.022","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T08:31:16Z","timestamp":1697877076000},"page":"1284-1288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["NOVATIVE: A Phase II\/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis"],"prefix":"10.1016","volume":"45","author":[{"given":"Andrea","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Pisella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Ben\u00edtez-del-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Amrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bremond-Gignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.09.022_bib0001","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0002","article-title":"Vernal keratoconjunctivitis: state of art and update on treatment","volume":"92","author":"Brindisi","year":"2021","journal-title":"Acta Biomed"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0003","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/ph14070658","article-title":"Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives","volume":"14","author":"Chigbu","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0004","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/pai.12197","article-title":"Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes","volume":"25","author":"Vichyanond","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jtos.2022.08.009","article-title":"The multifaceted aspects of ocular allergies: phenotypes and endotypes","volume":"26","author":"Bonini","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0006","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/pai.13520","article-title":"Health-related quality of life in children at the diagnosis of vernal keratoconjunctivitis","volume":"32","author":"Artesani","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamaophthalmol.2021.1708","article-title":"Association of allergic conjunctivitis with health-related quality of life in children and their parents","volume":"139","author":"Zhang","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0008","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2012.03.041","article-title":"Vernal keratoconjunctivitis in school children in Rwanda: clinical presentation, impact on school attendance, and access to medical care","volume":"119","author":"De Smedt","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/08820538.2015.1123737","article-title":"Impact of vernal keratoconjunctivitis on school children in Egypt","volume":"32","author":"Marey","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0011","first-page":"410","article-title":"Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis","volume":"56","author":"Coban-Karatas","year":"2014","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.17219\/acem\/37145","article-title":"Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial","volume":"23","author":"Keklikci","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0013","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2011.07.004","article-title":"Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study","volume":"128","author":"Lambiase","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0014","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":"Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0015","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","article-title":"Topical cyclosporine in vernal keratoconjunctivitis","volume":"98","author":"Bleik","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","article-title":"Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial","volume":"96","author":"De Smedt","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"pt 1","key":"10.1016\/j.clinthera.2023.09.022_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0021","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/ijms18071558","article-title":"Surface chemistry interactions of Cationorm with films by human meibum and tear film compounds","volume":"18","author":"Georgiev","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0022","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0024","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-022-02342-6","article-title":"Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials","author":"Leonardi","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0026","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis","volume":"101","author":"BenEzra","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0028","series-title":"Withdrawal assessment report for vekacia","year":"2009"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0029","article-title":"Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining score","volume":"8","author":"Leonardi","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.clinthera.2023.09.022_bib0030","first-page":"1","article-title":"Efficacy and Satisfaction of Cyclosporine 0.1% in Patients with Vernal Keratoconjunctivitis","author":"Salami","year":"2022","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:40Z","timestamp":1758963640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823003880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0149291823003880"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NOVATIVE: A Phase II\/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}